No abstract

Thalassemia is a congenital hemolytic disorder caused by a partial or complete deficiency of ␣-or ␤-globin chain synthesis. Homozygous carriers of ␤-globin gene defects suffer from severe anemia and other serious complications from early childhood. The disease is treated by chronic blood transfusion. However, this can cause severe iron overload resulting in progressive organ failure. Some forms of ␣ thalassemia are also associated with a similar clinical picture. Despite the difficulties associated with treatment, standards of care for thalassemic patients have improved in recent years, resulting in almost doubling of the average life expectancy. As a consequence, additional previously undescribed, complications are now being recognized. In particular, profound hemostatic changes have been observed in patients with ␤-thalassemia major (␤-TM) and ␤-thalassemia intermedia (␤-TI) and also in patients with ␣ thalassemia (hemoglobin H disease). The presence of a higher than normal incidence of thromboembolic events, mainly in ␤-TI, and the existence of prothrombotic hemostatic anomalies in the majority of the patients, even from a very young age, have led to the recognition of the existence of a chronic hypercoagulable state in thalassemic patients. Despite the appearance of numerous publications on the frequent occurrence of thromboembolic complications in thalassemia, this complication has not been emphasized or comprehensively reviewed. This review summarizes the current literature and discusses possible mechanisms of the lifelong hypercoagulable state that exists in thalassemia. (Blood. 2002;99:36-43)

Progressive iron overload is the most salient and ultimately fatal complication of ␤-thalassemia. However, little is known about the relationship among ineffective erythropoiesis (IE), the role of iron-regulatory genes, and tissue iron distribution in ␤-thalassemia. We analyzed tissue iron content and iron-regulatory gene expression in the liver, duodenum, spleen, bone marrow, kidney, and heart of mice up to 1 year old that exhibit levels of iron overload and anemia consistent with both ␤-thalassemia intermedia (th3/؉) and major (th3/th3). Here we show, for the first time, that tissue and cellular iron distribution are abnormal and different in th3/؉ and th3/th3 mice, and that transfusion therapy can rescue mice affected by ␤-thalassemia major and modify both the absorption and distribution of iron. Our study reveals that the degree of IE dictates tissue iron distribution and that IE and iron content regulate hepcidin (Hamp1) and other iron-regulatory genes such as Hfe and Cebpa. In young th3/؉ and th3/th3 mice, low Hamp1 levels are responsible for increased iron absorption. However, in 1-year-old th3/؉ animals, Hamp1 levels rise and it is rather the increase of ferroportin (Fpn1) that sustains iron accumulation, thus revealing a fundamental role of this iron transporter in the iron overload of ␤-thalasse- Introduction␤-Thalassemia is the most common congenital hemolytic anemia due to partial or complete lack of synthesis of ␤-globin chains. Cooley anemia, 1 also known as ␤-thalassemia major, is the most severe form of ␤-thalassemia, which is characterized by profound ineffective erythropoiesis (IE) requiring regular red blood cell (RBC) transfusions to sustain life. Transfusion therapy leads to excess iron accumulation in many organs resulting in tissue damage. Therefore, iron chelation is essential in the management of this otherwise fatal disease. 2 In ␤-thalassemia intermedia, in which a larger amount of ␤-globin chains are synthesized, the clinical picture is milder and the patients do not require frequent transfusions. However, progressive iron overload still occurs due to increased gastrointestinal (GI) iron absorption. [3][4][5] Studies in thalassemic patients showed that the rate of iron uptake from the GI tract is approximately 3 to 4 times greater than normal. 6 Ferrokinetic studies revealed that 75% to 90% of the iron in donor serum, labeled with 59 Fe and injected into healthy subjects, appeared in circulating red cells within 7 to 10 days. In some thalassemic patients, however, only 15% of the 59 Fe was incorporated into circulating erythrocytes. 7 This discrepancy was attributed to the fact that iron would be sequestered in those organs in which premature destruction of erythroid precursors occurs. In ␤-thalassemia, it has been suggested that 60% to 80% of erythroid precursors die in the marrow and extramedullary sites. [8][9][10] Therefore, in ␤-thalassemia erythropoietic organs such as the bone marrow (BM) in humans and the BM and spleen in mice would be expected to show the highest iron concen...